We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -0.06% | 1,809.00 | 1,809.00 | 1,810.00 | 1,814.50 | 1,805.00 | 1,811.00 | 969,531 | 12:57:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.15 | 74.64B |
From May 2022 to May 2024
By Denny Jacob
International stocks trading in New York closed higher on Tuesday.
The S&P/BNY Mellon index of American depositary receipts rose 1% to 145.96. The European index gained 1.4% to 142.24. The Asian index edged up 0.4% to 168.19. The Latin American index ticked up 0.3% to 180.98, while the emerging-markets index advanced 1% to 279.50.
Credit Suisse Group AG was among those whose ADRs traded actively.
The Swiss lender edged down 1.2% after disclosing that it found material weaknesses in its financial reporting over the past two years because of ineffective internal controls. The ADRs registered a 4.5% decline on Monday.
GSK PLC edged up 0.6% after the pharmaceutical giant said its Nucala add-on maintenance treatment for adults with severe eosinophilic asthma has been accepted for a new drug application in China. It also said in a separate announcement that data from a Phase 3 study showed that its vaccine candidate against the bacteria that causes meningitis and septicaemia met all primary endpoints.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 14, 2023 18:36 ET (22:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
